- Home
- PHM vs WAT Comparison
PHM vs WAT Comparison
Compare PHM & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHM
- WAT
- Stock Information
- Founded
- PHM 1950
- WAT 1958
- Country
- PHM United States
- WAT United States
- Employees
- PHM N/A
- WAT N/A
- Industry
- PHM Homebuilding
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- PHM Consumer Discretionary
- WAT Industrials
- Exchange
- PHM Nasdaq
- WAT Nasdaq
- Market Cap
- PHM 27.0B
- WAT 17.8B
- IPO Year
- PHM N/A
- WAT 1995
- Fundamental
- Price
- PHM $134.10
- WAT $303.66
- Analyst Decision
- PHM Buy
- WAT Hold
- Analyst Count
- PHM 14
- WAT 14
- Target Price
- PHM $136.71
- WAT $374.07
- AVG Volume (30 Days)
- PHM 2.0M
- WAT 582.8K
- Earning Date
- PHM 10-21-2025
- WAT 10-31-2025
- Dividend Yield
- PHM 0.66%
- WAT N/A
- EPS Growth
- PHM 2.26
- WAT 10.77
- EPS
- PHM 13.40
- WAT 11.09
- Revenue
- PHM $17,694,541,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- PHM N/A
- WAT $7.19
- Revenue Next Year
- PHM $0.08
- WAT $6.40
- P/E Ratio
- PHM $10.00
- WAT $27.46
- Revenue Growth
- PHM 5.04
- WAT 5.89
- 52 Week Low
- PHM $88.07
- WAT $275.05
- 52 Week High
- PHM $149.47
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- PHM 55.56
- WAT 53.25
- Support Level
- PHM $131.38
- WAT $294.96
- Resistance Level
- PHM $139.69
- WAT $303.24
- Average True Range (ATR)
- PHM 3.77
- WAT 9.27
- MACD
- PHM -0.86
- WAT 0.81
- Stochastic Oscillator
- PHM 37.28
- WAT 69.33
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.